Vanta Bioscience (BOM:540729) Shares Outstanding (EOP): 7.11 Mil (As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

BOM:540729 Vanta Bioscience Ltd BOM:540729
50 GF Score
Price ₹25.29
GF Value ₹11.96
Valuation Significantly Overvalued
! 10 Warning Signs
View Full Analysis

What is Vanta Bioscience Shares Outstanding (EOP)?

Vanta Bioscience BOM:540729 50 Shares Outstanding (EOP) is 7.11 Mil as of Mar. 2026. GuruFocus rates BOM:540729 with a GF Score™ of 50/100 and a GF Value™ of ₹11.96 (Significantly Overvalued). The stock has 10 warning signs investors should review.

Shares outstanding are shares that have been authorized, issued, and purchased by investors and are held by them. Vanta Bioscience's shares outstanding for the quarter that ended in Mar. 2026 was 7.11 Mil.

Vanta Bioscience's quarterly shares outstanding stayed the same from Sep. 2025 (7.11 Mil) to Mar. 2026 (7.11 Mil).

Vanta Bioscience's annual shares outstanding increased from Mar. 2025 (6.31 Mil) to Mar. 2026 (7.11 Mil). It means Vanta Bioscience issued new shares from Mar. 2025 to Mar. 2026 .


Vanta Bioscience  (BOM:540729) Shares Outstanding (EOP) Explanation

A company may buy back shares or issue shares in any fiscal period. If a company buys back shares, we should observe that the total number of shares decline. If the company issues new shares, the number of shares outstanding increases.

Usually the presence of treasury shares and a history of buyback are good indicators that company has competitive advantage. But studies have shown that companies usually buy back at wrong time. Buying back shares below its intrinsic value increases value for remaining shareholders. Buying back overvalued shares destroys value for existing shareholders.


Be Aware

Warren Buffett looks for consistency and upward long term trend. Because of share repurchase it is possible for net earnings trend to differ from EPS trend. He preferred net income over EPS. The companies with durable competitive advantage companies report higher % net earnings to total revenues.

Important: If a company is showing net earnings history greater than 20% on total revenues, it is probably benefiting from a long term competitive advantage.

If net earnings is less than 10%, likely to be in a highly competitive business.


Vanta Bioscience Shares Outstanding (EOP) Related Terms


Vanta Bioscience Shares Outstanding (EOP) Historical Data

* Premium members only.

The historical data trend for Vanta Bioscience's Shares Outstanding (EOP) can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Vanta Bioscience Shares Outstanding (EOP) Chart

Vanta Bioscience Annual Data
Trend Mar17 Mar18 Mar19 Mar20 Mar21 Mar22 Mar23 Mar24 Mar25 Mar26
Shares Outstanding (EOP)
Get a 7-Day Free Trial Premium Member Only Premium Member Only 6.31 6.31 6.31 6.31 7.11

Vanta Bioscience Semi-Annual Data
Mar17 Sep17 Mar18 Sep18 Mar19 Sep19 Mar20 Sep20 Mar21 Sep21 Mar22 Sep22 Mar23 Sep23 Mar24 Sep24 Mar25 Sep25 Mar26
Shares Outstanding (EOP) Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 6.31 6.31 6.31 7.11 7.11

BOM:540729 vs TMO, DHR, IDXX: Shares Outstanding (EOP) Comparison

For the Diagnostics & Research subindustry, Vanta Bioscience's Shares Outstanding (EOP), along with its competitors' market caps and Shares Outstanding (EOP) data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Vanta Bioscience Shares Outstanding (EOP) vs Medical Diagnostics & Research Industry

For the Medical Diagnostics & Research industry and Healthcare sector, Vanta Bioscience's Shares Outstanding (EOP) distribution charts can be found below:

* The bar in red indicates where Vanta Bioscience's Shares Outstanding (EOP) falls into.


BOM:540729
50GF Score
Vanta Bioscience Ltd BOM:540729
Shares Outstanding (EOP) is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Vanta Bioscience Shares Outstanding (EOP) Calculation

Shares outstanding are shares that have been authorized, issued, and purchased by investors and are held by them. They have voting rights and represent ownership in the corporation by the person that holds the shares. They should be distinguished from treasury shares, which are shares held by the corporation itself, having no exercisable rights.

Shares outstanding can be calculated as either basic or fully diluted. The fully diluted shares outstanding count includes diluting securities, such as options, warrants or convertibles.

Please note: GuruFocus named Shares Outstanding (EOP) is the shares for that end of period. It is usually used to calculate balance sheet related items, such as Book Value per Share, etc. While Shares Outstanding (Diluted Average) and Shares Outstanding (Basic Average) are the weighted average shares over a period of time (a year, a quarter, or so). They are usually used to calculate income statement or cashflow statement related items, such as Earnings per Share (Diluted), etc.

What does a Shares Outstanding (EOP) of 7.11 Mil mean?
Vanta Bioscience (BOM:540729) has a Shares Outstanding (EOP) of 7.11 Mil as of Mar. 2026. The total shares a company has outstanding, at period-end. View historical data on Vanta Bioscience and its competitors.
Is Vanta Bioscience's Shares Outstanding (EOP) too high?
Vanta Bioscience's current Shares Outstanding (EOP) is 7.11 Mil. Overall, Vanta Bioscience has a GF Score™ of 50/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Vanta Bioscience's Shares Outstanding (EOP) compare to TMO and DHR?
Vanta Bioscience's Shares Outstanding (EOP) of 7.11 Mil can be compared against companies in the Medical Diagnostics & Research industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Shares Outstanding (EOP) for a Medical Diagnostics & Research company?
A good Shares Outstanding (EOP) depends on the Medical Diagnostics & Research industry context. However, Shares Outstanding (EOP) should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Shares Outstanding (EOP) mean?
A high Shares Outstanding (EOP) can signal that a stock is expensive relative to its fundamentals. The total shares a company has outstanding, at period-end. View historical data on Vanta Bioscience and its competitors. Vanta Bioscience's current Shares Outstanding (EOP) is 7.11 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Vanta Bioscience stock overvalued right now?
Based on GuruFocus' analysis, Vanta Bioscience (BOM:540729) is currently considered Significantly Overvalued. The stock's GF Value™ is ₹11.96, compared to a current price of ₹25.29 — trading 111.5% above its estimated fair value. The current Shares Outstanding (EOP) is 7.11 Mil. Vanta Bioscience's overall GF Score™ is 50/100 with 10 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Shares Outstanding (EOP) calculated?
Shares Outstanding (EOP) is calculated from a company's financial statements. For Vanta Bioscience (BOM:540729), the current Shares Outstanding (EOP) is 7.11 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Vanta Bioscience (BOM:540729) Overvalued in 2026?

Based on GuruFocus' analysis, Vanta Bioscience stock appears to be overvalued. The current stock price of ₹25.29 is trading 111.5% above its estimated GF Value™ of ₹11.96. GuruFocus considers Vanta Bioscience to be Significantly Overvalued.

Key valuation signals for BOM:540729:

  • Shares Outstanding (EOP): 7.11 Mil
  • GF Value™: ₹11.96 vs. price of ₹25.29 (111.5% above fair value)
  • GF Score™: 50/100 with 10 warning signs

No single metric tells the full story. See the BOM:540729 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Vanta Bioscience Business Description

Address No. 02/G/308/G, Umajay Complex, No. 3/FF/SF/1-20-248, Rasoolpura, Secunderabad, TG, IND, 500003
Vanta Bioscience Ltd is a full-service preclinical contract research organization based in Chennai, India, providing preclinical safety assessment services for the pharmaceutical, medical devices, nutraceuticals, biotech, agrochemicals, cosmetics, chemical, and feed additive industries. Established as a center of excellence in GLP-compliant toxicology and safety assessment, the company supports clients through toxicology studies, batch release tests, biocompatibility evaluations, agro-chemical and chemical safety assessments, and diet formulation services. It also offers testing and contract research services in clinical and pre-clinical research, biopharma studies, analytical testing, and environmental assessments.
50GF Score

Get the complete analysis for BOM:540729

Shares Outstanding (EOP) is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

₹25.29
Price
₹11.96
GF Value